A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors

  • Hui K. Gan
  • Paul L. Mitchell
  • Peter Galettis
  • Ian D. Davis
  • Jonathan Cebon
  • Paul de Souza
  • Matthew Links
Original Article

Abstract

Purpose: This dose escalation study aimed to determine the recommended doses, toxicity and pharmacokinetics of oxaliplatin and gemcitabine given on days 1 and 8 every 21 days. This schedule may maximize dose intensity of both drugs with acceptable or reduced toxicity. Patient and methods: Eligible patients had solid malignancies, no more than two prior courses of chemotherapy, ECOG performance status 0–2, neurotoxicity ≤ NCI-CTC grade 1 and adequate organ function. Dose escalation commenced at oxaliplatin 40 mg/m2 and gemcitabine 750 mg/m2, both given on days 1 and 8 every 21 days, and reached oxaliplatin 80 mg/m2 and gemcitabine 1,500 mg/m2. The two highest dose levels were each expanded to six patients to gain additional toxicity data. Results: There were no dose limiting toxicities related to treatment and an MTD was not reached. Five patients (24%) had grade 3 neutropenia, without associated infection, and seven patients (33%) had grade 3/4 thrombocytopenia. Neurotoxicity was mild and no worse than grade 1. Two patients with mesothelioma (10%) had partial responses and 11 patients (52%) had disease stabilization. No pharmacokinetic interaction between oxaliplatin and gemcitabine was detected. Dose intensity was maximal at level 4 (oxaliplatin 70 mg/m2 and gemcitabine 1,250 mg/m2). Conclusions: This schedule allows oxaliplatin and gemcitabine to be delivered at the full dose intensity of each drug with excellent tolerability and predictable pharmacokinetics. The recommended doses for phase II studies are oxaliplatin 70 mg/m2 and gemcitabine 1,250 mg/m2 on days 1 and 8 every 21 days.

Keywords

Gemcitabine Oxaliplatin Phase 1 Neurotoxicity Pharmacokinetics Mesothelioma 

Notes

Acknowledgments

Ms Jacqui Laird, Ms Jenny Smith, Supported in part by: Sanofi-Synthelabo and Eli-Lilly Previously presented in part: Annual Conference of the American Society of Clinical Oncology (2002, abstract 2129).

References

  1. 1.
    Albers P, Siener R, Hartlein M, Fallahi M, Haeutle D, Perabo FG, Steiner G, Blatter J, Muller SC (2002) Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma—prognostic factors for response and improvement of quality of life. Onkologie 25:47–52PubMedCrossRefGoogle Scholar
  2. 2.
    Andre T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, Selle F, Paye F, Hannoun L, Houry S, Gayet B, Lotz JP, de Gramont A, Louvet C (2004) Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 15:1339–1343PubMedCrossRefGoogle Scholar
  3. 3.
    Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J, Melemed A (2002) Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology 62: 2–8PubMedCrossRefGoogle Scholar
  4. 4.
    Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, Herrmann R, Pestalozzi BC, Saletti P, Hanselmann S, Muller S, Brauchli P, Castiglione-Gertsch M, Goldhirsch A, Roth AD (2002) Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 20:1759–1766PubMedCrossRefGoogle Scholar
  5. 5.
    Caussanel JP, Levi F, Brienza S, Misset JL, Itzhaki M, Adam R, Milano G, Hecquet B, Mathe G (1990) Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 82:1046–1050PubMedCrossRefGoogle Scholar
  6. 6.
    Crino L, Mosconi AM, Calandri C, Corgna E, Porrozzi S, Chiara S, Nobili MT, Tonato M (2001) Gemcitabine in advanced pancreatic cancer: a phase II trial. Am J Clin Oncol 24:296–298PubMedCrossRefGoogle Scholar
  7. 7.
    de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938–2947PubMedGoogle Scholar
  8. 8.
    Diaz-Rubio E, Sastre J, Zaniboni A, Labianca R, Cortes-Funes H, de Braud F, Boni C, Benavides M, Dallavalle G, Homerin M (1998) Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 9:105–108PubMedCrossRefGoogle Scholar
  9. 9.
    Dieras V, Bougnoux P, Petit T, Chollet P, Beuzeboc P, Borel C, Husseini F, Goupil A, Kerbrat P, Misset JL, Bensmaine MA, Tabah-Fisch I, Pouillart P (2002) Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/− taxane-pretreated ovarian cancer patients. Ann Oncol 13:258–266PubMedCrossRefGoogle Scholar
  10. 10.
    Ducreux M, Mitry E, Ould-Kaci M, Boige V, Seitz JF, Bugat R, Breau JL, Bouche O, Etienne PL, Tigaud JM, Morvan F, Cvitkovic E, Rougier P (2004) Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. Ann Oncol 15:467–473PubMedCrossRefGoogle Scholar
  11. 11.
    Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M (1990) Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25:299–303PubMedCrossRefGoogle Scholar
  12. 12.
    Extra JM, Marty M, Brienza S, Misset JL (1998) Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 25:13–22PubMedGoogle Scholar
  13. 13.
    Faivre S, Le Chevalier T, Monnerat C, Lokiec F, Novello S, Taieb J, Pautier P, Lhomme C, Ruffie P, Kayitalire L, Armand JP, Raymond E (2002) Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. Ann Oncol 13:1479–1489PubMedCrossRefGoogle Scholar
  14. 14.
    Fennell DA, JP CS, Shamash J, Sheaff MT, Evans MT, Goonewardene TI, Nystrom ML, Gower NH, Rudd RM (2005) Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma. Lung Cancer 47:277–281PubMedCrossRefGoogle Scholar
  15. 15.
    Fizazi K, Doubre H, Le Chevalier T, Riviere A, Viala J, Daniel C, Robert L, Barthelemy P, Fandi A, Ruffie P (2003) Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. J Clin Oncol 21: 349–354PubMedCrossRefGoogle Scholar
  16. 16.
    Franciosi V, Barbieri R, Aitini E, Vasini G, Cacciani GC, Capra R, Camisa R, Cascinu S (2003) Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patients. Lung Cancer 41:101–106PubMedCrossRefGoogle Scholar
  17. 17.
    Freeman KB, Anliker S, Hamilton M, Osborne D, Dhahir PH, Nelson R, Allerheiligen SR (1995) Validated assays for the determination of gemcitabine in human plasma and urine using high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Appl 665:171–181PubMedCrossRefGoogle Scholar
  18. 18.
    Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W (1992) Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 10: 406–413PubMedGoogle Scholar
  19. 19.
    Kouroussis C, Souglakos J, Kakolyris S, Mavroudis D, Malamos N, Kalbakis K, Androulakis N, Agelaki A, Vardakis N, Samonis G, Georgoulias V (2001) Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: a phase II study. Oncology 61: 36–41PubMedCrossRefGoogle Scholar
  20. 20.
    Kouroussis C, Souglakos J, Mavroudis D, Papadouris S, Kakolyris S, Agelaki S, Kalbakis K, Panopoulos C, Vardakis N, Sarra E, Georgoulias V (2002) Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC). Am J Clin Oncol 25:627–631PubMedCrossRefGoogle Scholar
  21. 21.
    Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, Andre T, Zaniboni A, Ducreux M, Aitini E, Taieb J, Faroux R, Lepere C, de Gramont A, GERCOR, GISCAD (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509–3516Google Scholar
  22. 22.
    Machover D, Diaz-Rubio E, de Gramont A, Schilf A, Gastiaburu JJ, Brienza S, Itzhaki M, Metzger G, N’Daw D, Vignoud J, Abad A, Francois E, Gamelin E, Marty M, Sastre J, Seitz JF, Ychou M (1996) Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 7: 95–98PubMedGoogle Scholar
  23. 23.
    Maindrault-Goebel F, Louvet C, Andre T, Carola E, Lotz JP, Molitor JL, Garcia ML, Gilles-Amar V, Izrael V, Krulik M, de Gramont A (1999) Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). Eur J Cancer 35:1338–1342PubMedCrossRefGoogle Scholar
  24. 24.
    Massari C, Brienza S, Rotarski M, Gastiaburu J, Misset JL, Cupissol D, Alafaci E, Dutertre-Catella H, Bastian G (2000) Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Cancer Chemother Pharmacol 45:157–164PubMedCrossRefGoogle Scholar
  25. 25.
    Mavroudis D, Pappas P, Kouroussis C, Kakolyris S, Agelaki S, Kalbakis K, Androulakis N, Souglakos J, Vardakis N, Nikolaidou M, Samonis G, Marselos M, Georgoulias V (2003) A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors. Ann Oncol 14: 304–312PubMedCrossRefGoogle Scholar
  26. 26.
    Monnet I de Cremoux H, Soulie P, Saltiel-Voisin S, Bekradda M, Saltiel JC, Brain E, Rixe O, Yataghene Y, Misset JL, Cvitkovic E (2002) Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicenter phase II study. Ann Oncol 13:103–107CrossRefGoogle Scholar
  27. 27.
    Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, Mitchell P, Musk AW, Robinson BW (2002) A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 87: 491–496PubMedCrossRefGoogle Scholar
  28. 28.
    Pectasides D, Pectasides M, Farmakis D, Aravantinos G, Nikolaou M, Koumpou M, Gaglia A, Kostopoulou V, Mylonakis N, Skarlos D (2004) Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol 15: 493–497PubMedCrossRefGoogle Scholar
  29. 29.
    Ravaioli A, Marangolo M, Pasquini E, Rossi A, Amadori D, Cruciani G, Tassinari D, Oliverio G, Giovanis P, Turci D, Zumaglini F, Nicolini M, Panzini I (2002) Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer. J Clin Oncol 20: 2545–2550PubMedCrossRefGoogle Scholar
  30. 30.
    Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG (2003) Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21: 2059–2069PubMedCrossRefGoogle Scholar
  31. 31.
    Schuette W, Blankenburg T, Lauerwald K, Schreiber J, Bork I, Wollscgkaeger B, Treutler D, Schneider CP, Bonner R (2003) A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma. Clin Lung Cancer 4: 294–297CrossRefGoogle Scholar
  32. 32.
    Screnci D, Er HM, Hambley TW, Galettis P, Brouwer W, McKeage MJ (1997) Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin. Br J Cancer 76:502–510PubMedGoogle Scholar
  33. 33.
    van Meerbeeck JP, Baas P, Debruyne C, Groen HJ, Manegold C, Ardizzoni A, Gridelli C, van Marck EA, Lentz M, Giaccone G (1999) A phase II study of gemcitabine in patients with malignant pleural mesothelioma. Cancer 85:2577–2582PubMedCrossRefGoogle Scholar
  34. 34.
    Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644PubMedCrossRefGoogle Scholar
  35. 35.
    Wixley RAJ (1997) Testing AUC dose-proportionality in destructive toxicokinetics. Drug Inf J 31:529–549Google Scholar
  36. 36.
    Zatloukal P, Kanitz E , Magyar P, Jassem J, Krzakowski M, Pawlicki M, Petruzelka L, Chovan L, Pesek M, Janko C, Krejcy K (1998) Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study. Lung Cancer 22:243–250PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Hui K. Gan
    • 1
  • Paul L. Mitchell
    • 1
  • Peter Galettis
    • 2
  • Ian D. Davis
    • 1
  • Jonathan Cebon
    • 1
  • Paul de Souza
    • 2
  • Matthew Links
    • 2
  1. 1.Department of Medical Oncology and Ludwig Institute for Cancer ResearchAustin HospitalMelbourneAustralia
  2. 2.Department of Medical OncologySt George Hospital and University of New South WalesKogarahAustralia

Personalised recommendations